NPPB and AL amyloidosis: Serum levels of NT-proBNP and cardiac troponins have emerged as important prognostic parameters and are therefore commonly used for risk stratification.16 18 In an unselected population of patients with AL amyloidosis the prognostic value of these biomarkers results from separating patients with a low (MAYO stage I) from those with a high probability of cardiac involvement (MAYO stage>I).